Novo Nordisk A/S
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
Novo Nordisk and its subsidiaries research, develop, manufacture, and distribute pharmaceutical products.
The class action lawsuit alleges that throughout the Class Period, Novo Nordisk made false or misleading statements and failed to disclose that:
1. The company misrepresented the reliability of its projected success for the Phase 3 CagriSema obesity study, “REDEFINE-1,” while avoiding discussions about dosage tolerability.
2. Novo Nordisk’s optimistic claims that CagriSema would achieve at least 25% weight loss in REDEFINE-1 were unrealistic.
3. The study’s “flexible protocol” limited its ability to provide meaningful weight loss data on the tested dosage, suggesting that either tolerability issues forced patients to reduce dosages or that the selection process was rushed, enrolling patients who were not committed to achieving the 25% weight loss goal.
According to the complaint, on December 20, 2024, Novo Nordisk released headline results from the REDEFINE-1 trial, revealing that the flexible protocol allowed patients to adjust their dosing. The company reported that after 68 weeks, only 57.3% of CagriSema patients remained on the highest dose, compared to 82.5% for cagrilintide 2.4 mg and 70.2% for semaglutide 2.4 mg. Following this news, Novo Nordisk’s stock price dropped nearly 18%.
